Filing Details
- Accession Number:
- 0000899243-20-014410
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-28 16:05:28
- Reporting Period:
- 2020-05-26
- Accepted Time:
- 2020-05-28 16:05:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1629137 | Global Blood Therapeutics Inc. | GBT | Pharmaceutical Preparations (2834) | 274825712 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1730866 | Ann Lesley Calhoun | C/O Global Blood Therapeutics, Inc. 181 Oyster Point Blvd South San Francisco CA 94080 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-05-26 | 2,700 | $29.75 | 2,854 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-26 | 2,700 | $70.10 | 154 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-05-26 | 2,700 | $0.00 | 2,700 | $29.75 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 900 | 2027-02-28 | No | 4 | M | Direct |
Footnotes
- The Stock Option becomes exercisable in sixteen equal quarterly installments after March 1, 2017 until fully vested on March 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Billionaire Hedge Funds
